Aktienanalyse zu ArriVent BioPharma, Inc. (AVBP)AVBPArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 is a Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Arrivent Biopharma Inc (AVBP) is not a good buy. The stock has plummeted 48% following a failed clinical trial, and the current price is $16.66, significantly below recent analyst price targets ranging from $18 to $29. The RSI is at a low 25.154, indicating oversold conditions, but the overall financial outlook remains negative with a forward P/E of 0 and a net income loss of $49.89 million in Q2 2026. The main risk is the ongoing negative sentiment due to the trial failure, which has led to a drastic drop in stock price and market confidence.